Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland
Open Access
- 19 June 2008
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 123 (6) , 1344-1349
- https://doi.org/10.1002/ijc.23670
Abstract
A persistent high-risk human papillomavirus (hrHPV) infection is a necessary condition for developing a cervical intraepithelial neoplasia and cervical cancer. The viral aetiology in cervical carcinogenesis has stimulated attempts to use HPV DNA detection in cervical cancer screening. In Finland there is an ongoing study assessing the benefits of primary HPV DNA testing in the setting of centrally organised mass screening for cervical cancer. Here we present the age-specific prevalence of hrHPV infection and associated sociodemographic factors of 16,895 women aged 25–65 years attending the 5-yearly cervical cancer screening between years 2003 and 2004. The overall hrHPV prevalence rate was 7.5%. The peak prevalence at the age group of 25–29 was 24.1% decreasing steadily thereafter to approximately 2.9% in women aged 65 years. Young age and marital status were the main determinants for oncogenic HPV types. Our study confirms the inverse relationship between age and hrHPV prevalence reported in many developed countries. As our prevalence rates and hence background risk for cervical cancer are not lower than in other European countries, it is likely that our lowest cervical cancer burden in Europe is due to health care actions justifying the organised cervical cancer screening.Keywords
This publication has 34 references indexed in Scilit:
- Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3European Journal Of Cancer, 2008
- Human Papillomavirus and Papanicolaou Tests to Screen for Cervical CancerNew England Journal of Medicine, 2007
- Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trialThe Lancet, 2007
- Human Papillomavirus Prevalence in Women Who Have and Have Not Undergone HysterectomiesThe Journal of Infectious Diseases, 2006
- Chapter 9: Clinical applications of HPV testing: A summary of meta-analysesVaccine, 2006
- Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled TrialJNCI Journal of the National Cancer Institute, 2006
- Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised settingBritish Journal of Cancer, 2005
- Prevalence of human papillomavirus infection in women in Turin, ItalyEuropean Journal Of Cancer, 2005
- Cervical Human Papillomavirus Infection in the Female Population in Barcelona, SpainSexually Transmitted Diseases, 2003
- Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patientsBritish Journal of Cancer, 2003